# Cryoocyte AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cryoocyte

- Industry: Agribusiness
- Headquarters: Atlanta, US
- Website: www.cryoocyte.com
- Total disclosed funding: $4M
- Latest round: Series A (Oct 23, 2017)
- Investors on record: 2

## About

Cryoocyte AS is dedicated to enhancing aquaculture through innovative solutions that improve egg quality and optimize hatchery operations, thereby supporting sustainable seafood practices.Founded in 2016 and headquartered in Atlanta, US, Cryoocyte AS specializes in aquaculture solutions, with a focus on cryopreservation and incubation technologies. In October 2017, the company raised USD 4.000 mn in Series A funding, co-led by Aqua-Spark and Vodia Ventures. This funding round was pivotal for their growth, with a total of USD 4.000 mn raised to date. The founder's history is not specified in the available data.Cryoocyte specializes in innovative solutions for aquaculture, focusing on the optimization of egg quality and hatchery operations. The company's core offerings include proprietary cryopreservation techniques and specialized incubation systems designed to enhance the viability and growth rates of fish and seafood species. These products serve a range of stakeholders within the aquaculture industry, including hatcheries, fish farmers, and seafood processors, all of whom benefit from improved yield and efficiency in their operations. Cryoocyte’s technology aims to address critical challenges such as declining fish populations and sustainability in aquaculture practices. The company's products are marketed primarily in regions with established aquaculture industries, including North America, Europe, and parts of Asia, where demand for sustainable seafood solutions is rising.Cryoocyte's revenue generation is primarily structured around B2B transactions, collaborating with hatcheries and aquaculture businesses to implement advanced cryopreservation and incubation solutions. Partnerships involve one-time sales of equipment as well as ongoing service contracts for maintenance and support. Cryoocyte’s flagship products are priced to reflect their innovative nature and the value they provide in enhancing production efficiencies. Clients engage through direct negotiations, leading to agreements that may include volume discounts for larger orders or subscription-like models for ongoing technical support and product updates. This transactional framework is designed to foster long-term client relationships, ensuring continuous access to advanced technologies that drive profitability and sustainability in operations.Cryoocyte AS plans to leverage the recent Series A funding of USD 4.000 mn raised in October 2017 to accelerate the development of new products and enhance its market position. The company is focused on expanding its offerings and plans to introduce additional products addressing industry needs. Target markets for expansion include regions in Asia where aquaculture is rapidly growing, with specific initiatives planned for the next three years. The funding will support these product innovations and market entry strategies, positioning Cryoocyte to address increasing demand for sustainable aquaculture solutions.

## Funding rounds

- Series A, Oct 23, 2017, $4M — Vodia Ventures, Aqua-Spark

## Investors

- Vodia Ventures (https://capitalatlas.ai/funds/vodia-ventures) — Series A
- Aqua-Spark (https://capitalatlas.ai/funds/aqua-spark) — Series A